Form 4: Neogenomics Executive Alicia C. Olivo Reports Stock Transactions
SEC Form 4 Filing
Alicia C. Olivo, General Counsel of Neogenomics, reports the surrender of shares to cover tax obligations related to vesting restricted stock and details holdings of stock options and restricted stock units.
Summary
- On September 1, 2024, Alicia C. Olivo, General Counsel of Neogenomics, surrendered 1,666 shares of common stock to cover tax obligations related to the vesting of restricted stock.
- Following this transaction, Ms. Olivo directly owns 42,147 shares of Neogenomics common stock.
- The report also details Ms. Olivo's holdings of various stock options and restricted stock units with different exercise prices, grant dates, and vesting schedules.
- These include options to buy common stock at prices ranging from $9.45 to $48.99, and performance stock units and restricted stock units that vest over time based on service and/or performance criteria.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't convey any explicit positive or negative sentiment about the company's performance or prospects.
Future Outlook
The vesting of performance stock units is contingent upon the achievement of certain share growth and/or revenue growth goals, indicating a potential for future stock ownership changes based on company performance.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the holdings and transactions of key personnel.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are standard components of executive compensation packages in the biotechnology and diagnostics industries.
- Companies like Exact Sciences, Guardant Health, and Invitae also utilize similar equity-based compensation to incentivize and retain key employees.
- The vesting schedules and performance criteria associated with these grants are generally aligned with industry best practices to drive long-term value creation.
Stakeholder Impact
- The filing provides transparency to shareholders regarding executive compensation and stock ownership.
- It assures stakeholders that executives' interests are aligned with those of the shareholders through equity-based compensation.
Key Dates
| Date | Description |
|---|---|
| 09/30/2019 | Ms. Olivo was granted 1,394 stock options. |
| 05/01/2020 | Ms. Olivo was granted 1,024 stock options. |
| 05/01/2021 | Ms. Olivo was granted 516 stock options. |
| 08/01/2021 | Ms. Olivo was granted 1,117 stock options. |
| 05/01/2022 | Ms. Olivo was granted 22,222 stock options. |
| 09/01/2022 | Ms. Olivo was granted 55,332 stock options. |
| 05/11/2023 | Ms. Olivo was granted 36,508 stock options, 19,508 performance stock units, and 19,508 restricted stock units. |
| 02/23/2024 | Ms. Olivo was granted 42,344 stock options, 25,330 performance stock units, and 25,329 restricted stock units. |
| 09/01/2024 | Ms. Olivo surrendered 1,666 shares of common stock to cover tax obligations. |
| 09/04/2024 | Date of the report. |
| 09/30/2026 | Expiration date for some stock options. |
| 05/01/2027 | Expiration date for some stock options. |
| 05/01/2028 | Expiration date for some stock options. |
| 08/01/2028 | Expiration date for some stock options. |
| 05/01/2029 | Expiration date for some stock options. |
| 09/01/2029 | Expiration date for some stock options. |
| 05/11/2030 | Expiration date for some stock options. |
| 02/23/2034 | Expiration date for some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.